Xylem Q1 revenue rises 3% to $2.1 billion; raises 2026 revenue outlook
Xylem reported first-quarter 2026 revenue of $2.1 billion, up 3% on a reported basis but flat organically, and diluted EPS of $0.79, up 14%. Adjusted EPS was $1.12, up 9%. The company raised its full-year 2026 reported revenue forecast to $9.2 to $9.3 billion, while keeping its adjusted EPS guidance of $5.35 to $5.60 unchanged.
Key points
- Q1 2026 revenue of $2.1 billion, up 3% reported and flat organically; orders of $2.2 billion, up 3% reported
- Diluted EPS $0.79 vs. $0.69 a year earlier; adjusted EPS $1.12 vs. $1.03
- 2026 revenue guidance raised to $9.2 to $9.3 billion, up 2% to 3% reported, from 1% to 3% previously
- Adjusted EPS guidance of $5.35 to $5.60 kept in line with prior range; repurchases of common stock totaled $563 million in Q1
The filing
Written by AI on Nov 8, 2026, 12:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 28, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.